• February 25, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved SimparicaTM (sarolaner) Chewables to kill adult fleas and prevent flea infestations, as well as treat and control tick infestations due to the Lone Star tick, the Gulf Coast tick, the American dog tick, and the brown dog tick. Simparica is approved for use in dogs 6 months of age or older and weighing 2.8 pounds or more. In a single-dose, tastymore...
  • February 23, 2016
    PUERTO MONTT, CHILE - PHARMAQ's vaccine ALPHA JECT LiVac® SRS received a provisional marketing authorisation (PMA number 2320-BP) from the Chilean authority, Servicio Agrícola y Ganadero de Chile (SAG). "Our innovative drive is based on the aquaculture industry's need to produce safe and healthy seafood. We are confident that this ground-breaking vaccine will be an important tool to help fight SRS. This is a highly requested product by the industry and will help achieve more predictable andmore...
  • November 17, 2015
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that the European Commission has granted marketing authorization for SimparicaTM (sarolaner) chewable tablets, a once-monthly medication for the treatment of fleas, ticks and sarcoptic mange in dogs beginning at eight weeks of age. The approval follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use in September 2015. “The approval of Simparica givesmore...
  • November 2, 2015
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced an agreement to purchase PHARMAQ, the global leader in vaccines and innovation for health products in aquaculture, for a price of $765 million on a debt-free basis. Acquiring PHARMAQ strengthens Zoetis’ core livestock business, giving the company a market-leading presence in the fastest growing segment of the animal health industry. Zoetis is purchasing PHARMAQ from a company owned by Permira IV, amore...
  • February 10, 2015
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that it has completed the purchase of the animal health assets of Abbott for a purchase price of $255 million, having fulfilled all closing requirements. The purchase expands Zoetis’ companion animal product portfolio to bring veterinarians solutions for anesthesia and treating pain and serious illnesses such as diabetes. It also brings novel cancer and pain compounds to the Zoetis pipelinemore...
  • January 7, 2015
    FLORHAM PARK, N.J., Jan. 7, 2015 — Fostera® PRRS, from Zoetis, is now licensed for whole herd protection against both the respiratory and reproductive forms of disease caused by porcine reproductive and respiratory syndrome (PRRS) virus.The new reproductive claim, recently granted by the U.S. Department of Agriculture (USDA), allows for vaccination of sows and gilts prebreeding to help provide protection against the reproductive form of the disease. The new respiratory claim allows formore...
  • November 24, 2014
    DURHAM, N.C. - November 24, 2014 – Zoetis Inc. today announced the reintroduction of Zoamix® (zoalene), a versatile synthetic anticoccidial for the prevention and control of coccidiosis in broilers and turkeys.“The U.S. poultry industry loses an estimated $600 million a year to coccidiosis[i], so the return of Zoamix could not be coming at a better time,” said Don Waldrip, DVM, DACPV, a senior technical services veterinarian with Zoetis.He noted that U.S. poultry producers have not seen a newmore...
  • September 25, 2014
    FLORHAM PARK, NJ, Sept. 25, 2014 — Zoetis now offers a test to quickly and accurately screen for the detection of antibodies to Johne’s Disease in cattle, the company announced today.Matthew Krecic, DVM, MS, MBA, DACVIM, Senior Technical Services Manager of U.S. Diagnostics, Zoetis, said the test uses an indirect immunoenzymatic technique to detect Mycobacterium avium, subspecies paratuberculosis (M. ParaTB) antibodies in samples of cattle serum and plasma. Results are available in less thanmore...
  • September 3, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Department of Agriculture (USDA) has granted a conditional license for a vaccine to help fight porcine epidemic diarrhea virus (PEDv) in pigs. The two-dose inactivated vaccine, licensed for use in healthy pregnant female pigs (sows and gilts), is designed to help them develop antibodies which can be transmitted to their newborn piglets. Zoetis anticipates the vaccine will be available tomore...
  • August 20, 2014
    FLORHAM PARK, N.J., Aug. 20, 2014 — Fostera™ PCV MH — the porcine circovirus (PCV) and Mycoplasma hyopneumoniae (M. hyo) combination vaccine that was built from the ground up by Zoetis — now has the longest demonstrated duration of immunity (DOI) to help protect pigs from porcine circovirus-associated disease (PCVAD) caused by PCV Type 2 (PCV2). The U.S. Department of Agriculture has granted the combination vaccine the extended label claim of at least 23 weeks of protection against PCV2, whichmore...